Chris J. Schulze

Statistics

Publications

Citations

H-Index

Active since

2020

Affiliations

Revolution Medicines (United States)(Current)

Chris J. Schulze is an author at Revolution Medicines (United States) specializing in oncology, oncogenic signaling pathways, and cancer pharmacology.

Publications per year

2020–2022

Publications

Abstract 3595: RMC-6291, a next-generation tri-complex KRASG12C(ON) inhibitor, outperforms KRASG12C(OFF) inhibitors in preclinical models of KRASG12C cancers

Robert J. Nichols, Yu Chi Yang, Jim Cregg et al. · Cancer Research · 2022 · 34 citations

Medicine, Oncology, Pharmacology +17

A06 Tri-complex Inhibitors of the Oncogenic, GTP-Bound Form of KRASG12C Overcome RTK-Mediated Escape Mechanisms and Drive Tumor Regressions in Preclinical Models of NSCLC

R. Jeremy Nichols, Chris J. Schulze, Alun Bermingham et al. · Journal of Thoracic Oncology · 2020 · 23 citations · Full text

Medicine, Medicinal Chemistry, Oncology +16

Method for analyzing in-situ volume change of large format lithium-ion hard case cells

Chris J. Schulze, Kai Peter Birke · Journal of Energy Storage · 2022 · 17 citations

Engineering, Materials Engineering, Materials Science +11

1–3 of 3